Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Asıl Yazarlar: Ju Li (Yazar), Zhongyuan Zhang (Yazar), Xinhua Wu (Yazar), Jie Zhou (Yazar), Deqian Meng (Yazar), Ping Zhu (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...